Benign Prostatic Hyperplasia Implants Market Snapshot 2024-2028
Overview
Valued at ~$360.0 million in 2023, the benign prostatic hyperplasia (BPH) implants market is
projected to reach ~$532.2 million by 2028, increasing at a CAGR of 8.1% over
the 2023-2028 forecast period. This Market Snapshot is part of LSI’s Market Intelligence platform, your
one-stop-shop for global medtech market sizing and analysis, procedure volume data, startup company- and
deal-tracking, curated insights, and more.
BPH implants are an alternative therapy for the relief of symptoms associated with BPH in men, such as
incomplete voiding, urinary frequency, urgency, weak urinary stream, difficulty urinating, and sleep disruption.
BPH Implants are delivered via minimally invasive techniques through the urethra to mechanically expand and
retain the prostate tissue surrounding the urethra and reduce obstruction.
Products included within the scope of this analysis include:
Temporary and permanent implants placed via the urethra
This Market Snapshot is intended to provide a high-level overview of the global market for BPH implants, with
key insights into:
Unit volumes from 2023 to 2028
Market forecasts from 2023 to 2028
Market insights
Competitive landscape analysis of major competitors
Insights into key market events for strategic and startups
Benign Prostatic Hyperplasia Implants Market Snapshot Summary
| Snapshot Aspect | Data and Details |
| Base Year for Estimate | 2023 |
| Forecast Period | 2023 - 2028 |
| Market Size in 2023 | $360.0 million |
| CAGR | 8.1% |
| Projected Market Size in 2028 | $532.2 million |
Benign Prostatic Hyperplasia Implants Market Insights
The BPH implants market is poised for strong growth, driven by the increasing number of men worldwide suffering
from an enlarged prostate, with over 500 million affected. However, only a small percentage (about 0.2%) of
these men undergo surgical treatments for BPH each year, highlighting a significant opportunity for minimally
invasive procedures. Competitors in the interventional urology
market estimate that the Total Addressable Market (TAM) for BPH implants exceeds $1.5 billion.
While BPH implants face competition from alternative therapies such as holmium laser ablation (HoLEP),
transurethral prostatectomy (TURP), and water vaporization (e.g., Rezūm), they remain a popular choice due to
their simplicity and the reversibility of the procedure. Market growth in the latter part of the forecast period
is expected to be fueled by the entry of new suppliers alongside established players like Neotract/Teleflex,
Medi-Tate/Olympus, and Butterfly Medical, making the BPH implant market increasingly competitive and dynamic.
Competitive Landscape
The full Market Snapshot includes a robust analysis of the competitive landscape for the benign prostatic
hyperplasia implants market. This includes estimated market revenue and market share for key players, such as
Teleflex and Olympus.
Select Market Events
| Company | Date | Type | Event |
|
Olympus
|
3/2024 | Commercial Milestone | Olympus announced that the iTind BPH treatment device is now available on 13 GPO contracts in the United States. |
|
Teleflex
|
4/2024 | Commercial Launch | Teleflex announced the upcoming market release for its next-generation Urolift 2 implant, an FDA-cleared platform for treating BPH in all prostate types. |
Key Companies Covered
Butterfly Medical
Endotherapeutics
Olympus
ProArc Medical
ProVerum
Teleflex
Zenflow
